The efficacy of multi-agent DNA vaccines consisting of a truncated gene encoding Bacillus anthracis lethal factor (LFn) fused to either Yersinia pestis V antigen (V) or Y. pestis F1 was evaluated. A/J mice were immunized by gene gun and developed predominantly IgG1 responses that were fully protective against a lethal aerosolized B. anthracis spore challenge but required the presence of an additional DNA vaccine expressing anthrax protective antigen to boost survival against aerosolized Y. pestis.
Immunization against Bacillus anthracis is dependent upon the production of an effective antibody response directed against the bacterium's tripartite exotoxin comprised of protective antigen (PA, a nontoxic cell-binding element), lethal factor (LF, a metaloprotease), and edema factor (EF, a cyclic AMP modulator; Turnbull, 1991; Baillie & Read, 2001 ). This exotoxin is analogous to other AB-type toxins in that the A moiety contains the catalytic LF and EF subunits, while the B moiety, PA, serves to translocate EF and/or LF into the cytosol of the target cell (Baillie, 2009) . This translocation process is facilitated by the binding of PA to common regions within the N-terminal domains of LF (LFn) and EF and occurs in the absence of the toxic C-terminal domains of either protein. Indeed, it has been demonstrated that the coadministration of PA and LFn enhances the uptake of both antigens to heighten the magnitude of PA-and LFnspecific antibody responses and protect during a lethal anthrax spore infection (Price et al., 2001) . The combination of PA and LFn as a molecular syringe has been used to deliver antigens from HIV and Listeria monocytogenes fused to LFn to the cytoplasm of antigen-presenting cells (APCs; Ballard et al., 1996; Lu et al., 2000) . This approach effectively enhanced CD8 + and CD4 + T cell responses to the foreign antigens, highlighting its potential as a multi-agent vaccine delivery system for intracellular pathogens.
Multi-agent vaccines that confer protection against two or more diseases are highly desirable for biodefense applications because they reduce the number of vaccines an individual must receive resulting in increased compliance to a vaccination schedule. Like anthrax, immunization against Y. pestis requires an antibody response to two key antigens: Fraction 1 (F1, a component of the bacteria's capsule) and LcrV (V, involved in plague's type III secretion apparatus). In a previous study, we reported that the coadministration of a plasmid encoding PA enhanced the magnitude of the antibody response to V when it was expressed from a second plasmid and concluded that this effect was probably due to the presence of CpG motifs within the PA plasmid because V is not known to bind directly to PA (Williamson et al., 2002) . In the present study, we build upon this work by determining whether the protective immune response to anthrax and plague could be further enhanced by DNA vaccines expressing the PA/LFn molecular syringe and a V-LFn fusion. As antibody titers to F1 have been correlated with plague survival , we also constructed and evaluated a second fusion gene of LFn-F1.
Comparison of dissimilar vaccines often requires multiple animal models to bridge the results from multiple studies. Some of these animal models may not be optimal surrogates for the human disease or are not responsive to treatment (Riemenschneider et al., 2003) . To avoid the issue of animal model variability and demonstrate the combined efficacy of both the anthrax and plague DNA vaccine components during pathogen challenge, a common infection model was needed. A/J mice have been identified as an acceptable model for evaluating anthrax vaccines, while BALB/c mice are traditionally the strain of choice for Y. pestis challenge (Griffin et al., 2005) . However, unlike A/J mice, BALB/c mice are not susceptible to B. anthracis challenge in a clear dose-dependent manner (Beedham et al., 2001) . To establish the utility of A/J mice during Y. pestis challenges, 7-week-old, female, A/J (Harlan, UK) and BALB/c (Charles River, UK) mice were injected subcutaneously with a range of increasing doses (1-100 colony forming units, CFUs) of Y. pestis strain GB (Russell et al., 1995) . Both A/J and BALB/c mouse strains displayed similar susceptibilities to Y. pestis and died in a desired dose-dependent manner (Table 1) . Because both mouse strains behaved similarly, we hypothesized A/J mice would also be susceptible to aerosol challenge. Indeed, the A/J aerosol infection controls in the vaccination studies (Fig. 2 ) died in a reasonable timeframe and displayed symptoms consistent with a murine pulmonary plague infection. On the basis of these results, we concluded that the A/J mouse strain is an acceptable small animal challenge model for Y. pestis in addition to B. anthracis. Consequently, A/J mice were used for the remainder of the study.
The DNA vaccine templates for PA, V-LFn, and LFn-F1 were derived from the wild-type gene sequences (GenBank Accession numbers PA: AAA22637.1, LF: NC_001496.1, LcrV: NC_004839.1, F1: NC_00323.1) and codon maximized for human expression by GenScript USA, Inc. (Piscataway, NJ). The LFn/plague gene fusions encoded the first 254 amino acids of the fulllength LF protein with either an AG or TG linker. The orientation of these genes was based upon previous unpublished results indicating that V-LFn and LFn-F1 were the most promising constructs that would elicit an immune response that would be protective. Genes encoding the PA, V, and F1 DNA vaccines were fulllength and contained no deletions, in particular, the immunosuppressive domain of LcrV was not removed prior to optimization and cloning. All maximized genes were cloned into the eukaryotic expression vector, pDNAVACCultra2 (Nature Technology Corporation, Lincoln, NE), in-frame and downstream of the CMV promoter. Three DNA vaccines, phPA, phV-LFn, and phLFn-F1, were sequenced and expressed the appropriate protein with the correct size in Chinese hamster ovary (CHO) cells strain K1 (data not shown).
Immunogenicity of the constructs administered individually, or when co-coated on the same gold particle, was evaluated using a Helios TM gene gun (BioRad, Hercules, CA). DNA was precipitated onto 1 lm gold particles using polyvinylpyrrolidone as an adhesive (0.1 mg mL
À1
) and loaded onto Gold-Coat tubing using a Tubing Prep Station (BioRad) according to both manufacturer's instructions and Bennett et al. (1999) . The abdominal fur of 6-week-old, female, A/J mice (Harlan), in groups of six, was shaved prior to epidermal delivery of 1.0 lg of each DNA vaccine on days 0, 14, and 42. ELISAs were carried out on serum collected at day 56 and reported (mean lg mL À1 ± SEM) as described previously (Albrecht et al., 2007) . Antigen-specific immunoglobulin G (IgG) responses to the endogenously produced PA, LFn, V, and F1 proteins were dominated by IgG1 (Fig. 1) , indicative of a Th2 bias (Mosmann & Coffman, 1989) , and are consistent with gene gun delivery of DNA vaccines (Feltquate et al., 1997) . Co-delivery of phPA with either fusion construct did not abrogate the humoral response to LFn, V, or F1 as is often observed with multivalent DNA vaccines (Sedegah et al., 2004; Wang et al., 2007; Shen et al., 2009) . However, the magnitude of the antigen-specific titers was not enhanced by PA co-delivered with the LFn fusions. This may reflect a low extracellular concentration/dose following expression that may limit the potential of the LFn fusions to come in contact with and bind to PA. Previous reports demonstrating an additive immune response with PA and LFn used recombinant protein (Ballard et al., 1996; Lu et al., 2000) or targeted endogenously expressed PA and LFn from DNA vaccines to intracellular compartments (Price et al., 2001) . In general, the antibody responses to the quadra-valent cocktail were consistent with the single antigen or fusion formula; however, the anti-F1 response was significantly reduced (P = 0.05). This may reflect competition between the endogenously produced fusion proteins for the same binding site on PA following expression and cellular binding. Twenty-one days after the final immunization, the mice were aerosol challenged with either 2.75 9 10 4 B. anthracis STI (10 LD 50 ) spores per mouse or 1 9 10 5 CFU of Y. pestis GB (10 LD 50 ) per mouse using a Collison spray conditioned in a modified Henderson aerosol apparatus (Williamson et al., 2000) . Significance between groups was determined by log rank tests in conjunction with the Bonferroni multiple comparison method where P < 0.02 was defined as significant. The inhaled anthrax dose defeated 80% of the Fig. 1 . Gene gun immunization elicits a predominantly IgG1 response. Female A/J mice were vaccinated on days 0, 14, and 42 by ballistic gene gun with phPA, phV-LFn, and phLFn-F1 individually or co-formulated as trivalent or quadra-valent DNA vaccines. Antigen-specific IgG subclasses (IgG1 open bars and IgG2a solid bars) were measured by ELISA on day 56, 7 days prior to challenge, and are plotted as means ± SEM. PAspecific (a), LF-specific (b), F1-specific (c), and V-specific (d) titers were predominately IgG1, indicative of a Th2 bias. Titers were analyzed by ANOVA and Student-Newman-Keuls post-tests where P < 0.05 *, P < 0.01 **, and P < 0.001 ***. sham-vaccinated (pDNAVACCultra2 empty) mice, with a mean time to death (MTD) of 5 days. Groups receiving the PA and/or LFn expressing constructs were completely protected (100%, P < 0.02; Fig. 2a) , which is consistent with previous reports (Price et al., 2001; Hermanson et al., 2004; Livingston et al., 2010) and lends credence to the inclusion of nontoxic regions of LF in future anthrax vaccines (Baillie et al., 2010) . The plague challenge was also lethal in the sham and phPA-vaccinated mice, resulting in a MTD of 3 days (Fig. 2b) . Immunizations with phV-LFn or phLFn-F1 prolonged the MTD by 1 day relative to the sham (P < 0.02) but were still weakly protective against Y. pestis despite the relatively high antibody titers elicited by these fusions (Fig. 1c and d) . In contrast, the protective efficacy of the phV-LFn construct was enhanced following co-immunization with phPA (83% survival). Immunization with all three constructs was also modestly protective against plague (66%). The mechanism behind this enhancement remains unclear; as previously noted, the antibody titers to the fusions were not synergistically increased in the presence of phPA. It is feasible that the CpG motifs within the plasmid backbone provided additional, nonspecific immune-stimulation (Williamson et al., 2002) or the combination of PA and LFn fused to V facilitated an increase in the quality of the V-specific antibody response rather than its magnitude. This would manifest as an increase in the relative proportion of antibodies directed against protective, rather than nonprotective epitopes as a consequence of more efficient presentation to the MHC class II pathway. The results of the present study are highly encouraging and confirm the feasibility of developing a DNA-based vaccine approach that is capable of eliciting protective immune responses against anthrax and plague. Multiagent DNA vaccines targeting other dissimilar pathogens, notably viruses and bacteria, are already in development and show great promise (Riemenschneider et al., 2003) . One of the challenges facing researchers seeking to develop multivalent vaccines is the need to design formulations that ensure that the development of the responses to the individual antigens does not interfere with each other (Sedegah et al., 2004; Wang et al., 2007; Shen et al., 2009) . Fortunately, this was not observed in the antibody titers to the fusion vaccines; however, survival with the phV-LFn/phPA combination was slightly reduced by one animal (17%) when phLFn-F1 was included. This may reflect competition between the endogenously produced fusion proteins for the same binding site on PA following its expression and binding to the cell surface. Studies are currently in progress to characterize the basis of the immune enhancing effect observed during this study and to determine whether efficacy against plague can be enhanced as a consequence of codon modification or altering the DNA vaccine composition/formulation. Mice were immunized by pVAX-PA and survived a lethal anthrax infection. Twenty-one days after the final immunization, DNA-vaccinated mice were aerosol challenged with either Bacillus anthracis STI (a) or Yersinia pestis GB (b). The MTD for the sham vaccinations (pDNAVACCultra2 empty) was 5 days following anthrax challenge and 3 days following plague challenge. The anthrax survival rate with the PA and LFn fusions alone or in combination was significant relative to the sham vaccinations (P < 0.02) at 100%. The plague survival rates favoured the co-formulation of phV-LFn with phPA. Significance was determined by log rank tests in conjunction with the Bonferroni multiple comparison method where P < 0.02, identified by an asterisk, is significant.
